Diversified Trust Co grew its holdings in Elanco Animal Health (NYSE:ELAN) by 9.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 75,123 shares of the company’s stock after buying an additional 6,754 shares during the quarter. Diversified Trust Co’s holdings in Elanco Animal Health were worth $1,998,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at $32,000. Capital Investment Advisory Services LLC increased its position in shares of Elanco Animal Health by 1,501.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock worth $36,000 after purchasing an additional 1,051 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Elanco Animal Health by 376.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after purchasing an additional 1,130 shares in the last quarter. Zions Bancorporation N.A. increased its position in shares of Elanco Animal Health by 68.1% during the 2nd quarter. Zions Bancorporation N.A. now owns 1,750 shares of the company’s stock worth $59,000 after purchasing an additional 709 shares in the last quarter. Finally, Citizens Financial Group Inc RI increased its position in shares of Elanco Animal Health by 26.5% during the 2nd quarter. Citizens Financial Group Inc RI now owns 1,875 shares of the company’s stock worth $63,000 after purchasing an additional 393 shares in the last quarter.

Shares of NYSE ELAN traded up $0.19 during mid-day trading on Wednesday, hitting $26.87. The company’s stock had a trading volume of 11,806 shares, compared to its average volume of 5,626,950. The company’s fifty day simple moving average is $27.02 and its 200-day simple moving average is $31.14. Elanco Animal Health has a one year low of $25.51 and a one year high of $35.46. The stock has a market cap of $9.79 billion and a price-to-earnings ratio of 22.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.07 and a quick ratio of 1.71.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.02. The business had revenue of $781.60 million for the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The business’s revenue was up 1.5% compared to the same quarter last year. On average, sell-side analysts predict that Elanco Animal Health will post 1.08 EPS for the current year.

In related news, insider Michael-Bryant Hicks bought 11,030 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average cost of $26.65 per share, for a total transaction of $293,949.50. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Dawei Li acquired 1,384,717 shares of the stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $1.05 per share, for a total transaction of $1,453,952.85. Insiders have acquired a total of 1,497,497 shares of company stock worth $4,457,115 over the last 90 days. Corporate insiders own 0.04% of the company’s stock.

A number of equities research analysts recently issued reports on ELAN shares. Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research report on Monday, September 9th. They set a “positive” rating for the company. They noted that the move was a valuation call. Cleveland Research reiterated a “hold” rating on shares of Elanco Animal Health in a research report on Thursday, September 26th. Barclays started coverage on shares of Elanco Animal Health in a research report on Monday, September 23rd. They set an “overweight” rating and a $36.00 target price for the company. UBS Group upgraded shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and dropped their target price for the stock from $31.00 to $30.00 in a research report on Thursday, August 15th. Finally, Bank of America cut shares of Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 target price for the company. in a research report on Monday, August 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $33.98.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Further Reading: Why do companies pay special dividends?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.